Syntis Bio
June 16, 2025
Company Presentation
Metabolic Diseases
Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. The company is also developing a portfolio of enzyme replacement therapies to treat orphan metabolic diseases.
Company HQ City:
Boston
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2022
Lead Product in Development:
SYNT-101 is an oral obesity therapy that leverages the SYNT™ platform to transiently block duodenal nutrient absorption, mimicking the metabolic effects of gastric bypass surgery in a once-daily pill.
CEO
Rahul Dhanda
Year Founded
2022
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Three (3)
When you expect your next catalyst update?
Phase 1 Obesity Study
What is your next catalyst (value inflection) update?
March 2026
Website
https://syntis.bio/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}